Skip to main content
Animated patient portrayal of a father and son hiking

PROMACTA is a platelet booster, also known as a TPO-RA (thrombopoietin receptor agonist). This means that it boosts the number of platelets your child’s body makes.

PROMACTA is the only once-daily oral platelet booster that is available as a tablet and an oral suspension. It is also the only oral platelet booster approved to treat persistent or chronic immune thrombocytopenia (ITP) in children 1 year and older.

How PROMACTA treats persistent or chronic ITP

PROMACTA binds to TPO receptors like regular TPO to boost platelet production

A hormone called thrombopoietin (TPO) naturally creates platelets in the body and, unlike some other drugs used to treat persistent or chronic ITP, PROMACTA acts the same as TPO—working alongside your body to create more platelets.

PROMACTA is the only once-daily oral platelet booster that comes in both a tablet and an oral suspension, so even if your child can’t swallow a pill, they can still receive a once-daily oral therapy. Some other treatments for persistent or chronic ITP require doctor visits for an injection, while PROMACTA can be taken at home, at school, or on the go!

What makes PROMACTA different?

PROMACTA is the #1 prescribed platelet booster, taken by more than 500,000 people worldwide across all approved uses.*,†

For pediatric patients, it's the only once-daily oral TPO-RA treatment for persistent or chronic ITP, and it has the following features:

*Source: IQVIA claims data for March 2021 through August 2022.
Includes people with persistent or chronic immune thrombocytopenia, severe aplastic anemia, and chronic hepatitis C virus.

PROMACTA was studied in more pediatric patients than any other drug of its kind

PROMACTA has been proven to help pediatric patients with persistent or chronic immune thrombocytopenia (ITP) reach target platelet levels and maintain them for a long time.

Graph of 2 studies showing how PROMACTA works at 1 week. Both studies show PROMACTA vs Placebo
Graph of 2 studies showing how PROMACTA kept working at 6 to 8 weeks. Both studies show PROMACTA vs Placebo

 

 

Primary End Point

PETIT (Study 1): The primary end point was the proportion of patients achieving platelet counts ≥50,000/mcL at least once between Days 8 and 43 (Weeks 1 to 6) of the randomized period.

PETIT 2 (Study 2): The primary end point was the proportion of patients achieving platelet counts ≥50,000/mcL at least 6 of the 8 weeks between Weeks 5 to 12 of the randomized period.

Study Design

PETIT (Study 1): Open-label, double blind, randomized, placebo-controlled study to investigate the efficacy, safety, tolerability, and pharmacokinetics of eltrombopag in previously treated pediatric patients (n=67) with persistent or chronic ITP.

PETIT 2 (Study 2): Open-label, double-blind, randomized, placebo-controlled study to investigate the efficacy, safety, and tolerability of eltrombopag in previously treated pediatric patients (n=92) with chronic ITP.

PROMACTA helped in other ways

13% of patients (6 of 45) on PROMACTA needed to take rescue medication to raise their platelet levels compared with 50% of patients (11 of 22) on placebo

  • In a second study, 19% (12 of 63) on PROMACTA needed rescue medication versus 24% (7 of 29) on placebo

53% of patients (8 of 15) taking other ITP medications were able to reduce or stop using them after starting PROMACTA

  • In a second study, 46% of patients (6 of 13) taking PROMACTA reduced or stopped other ITP medications

Tap to see IMPORTANT SAFETY INFORMATION AND APPROVED USES

Important Safety Information for PROMACTA® (eltrombopag)

What is the most important information I should know about PROMACTA?

PROMACTA can cause serious side effects, including:

Liver problems.

What is the most important information I should know about PROMACTA?

PROMACTA can cause serious side effects, including:

Liver problems.
If you have chronic hepatitis C virus (HCV) and take PROMACTA with interferon and ribavirin treatment, PROMACTA may increase your risk of liver problems. If your health care provider tells you to stop treatment with interferon and ribavirin, you will also need to stop taking PROMACTA. 

PROMACTA may increase your risk of liver problems that may be severe and possibly life-threatening. Your health care provider will do blood tests to check your liver function before you start taking PROMACTA and during treatment. Your health care provider may stop your treatment with PROMACTA if you have changes in your liver function blood tests.

Tell your health care provider right away if you have any of these signs and symptoms of liver problems:

  • yellowing of the skin or the whites of the eyes (jaundice)
  • unusual darkening of the urine
  • unusual tiredness
  • right upper stomach area (abdomen) pain
  • confusion
  • swelling of the stomach area (abdomen)

What are the possible side effects of PROMACTA?

PROMACTA may cause serious side effects, including:

  • Worsening of a precancerous blood condition to a blood cancer called acute myelogenous leukemia (AML). PROMACTA is not for treatment of people with a precancerous condition called myelodysplastic syndromes (MDS). If you have MDS and receive PROMACTA, your MDS condition may worsen and become AML. If MDS worsens to become AML, you may die sooner from AML
  • High platelet counts and higher risk for blood clots. Your risk of getting a blood clot is increased if your platelet count is too high during treatment with PROMACTA. Your risk of getting a blood clot may also be increased during treatment with PROMACTA if you have normal or low platelet counts. You may have severe problems or die from some forms of blood clots, such as clots that travel to the lungs or that cause heart attacks or strokes. Your health care provider will check your blood platelet counts and change your dose or stop PROMACTA if your platelet counts get too high. Tell your health care provider right away if you have signs and symptoms of a blood clot in the leg such as swelling, pain, or tenderness.

    People with chronic liver disease may be at risk for a type of blood clot in the stomach area. Tell your health care provider right away if you have stomach area pain that may be a symptom of this type of blood clot
  • New or worsened cataracts (a clouding of the lens in the eye). New or worsened cataracts have happened in people taking PROMACTA. Your health care provider will check your eyes before and during your treatment with PROMACTA. Tell your health care provider about any changes in your eyesight while taking PROMACTA

What should I tell my health care provider before taking PROMACTA?

Before you take PROMACTA, tell your health care provider about all of your medical conditions, including if you:

  • have liver problems
  • have a precancerous condition called MDS or a blood cancer
  • have or have had a blood clot
  • have a history of cataracts
  • have had surgery to remove your spleen (splenectomy)
  • have bleeding problems
  • are of Asian ancestry (such as Chinese, Japanese, Taiwanese, or Korean). You may need a lower dose of PROMACTA
  • are pregnant or plan to become pregnant. It is not known if PROMACTA will harm an unborn baby. Tell your health care provider if you become pregnant or think you may be pregnant during treatment with PROMACTA. If you are a woman who is able to become pregnant, you must use reliable birth control (contraception) while taking PROMACTA and for at least 7 days after you stop taking PROMACTA. Talk to your health care provider about options of effective birth control methods that may be right for you during this time
  • are breastfeeding or plan to breastfeed. You should not breastfeed during treatment with PROMACTA. Talk to your health care provider about the best way to feed your baby during this time

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. PROMACTA may affect the way certain medicines work. Certain other medicines may affect the way PROMACTA works.

Especially tell your health care provider if you take:

  • certain medicines used to treat high cholesterol, called “statins”
  • a blood thinner medicine

Certain medicines may keep PROMACTA from working correctly. Take PROMACTA at least 2 hours before or 4 hours after taking these products:

  • antacids used to treat stomach ulcers or heartburn
  • multivitamins, mineral supplements, or products that contain iron, calcium, aluminum, magnesium, selenium, and zinc

Ask your health care provider if you are not sure if your medicine is one that is listed above.

Know the medicines you take. Keep a list of them and show it to your health care provider and pharmacist when you get a new medicine.

What should I avoid while taking PROMACTA?

Avoid situations and medicines that may increase your risk of bleeding.

The most common side effects of PROMACTA in adults when used to treat persistent or chronic immune thrombocytopenia (ITP) are:

  • nausea
  • diarrhea
  • upper respiratory tract infection (symptoms may include runny nose, stuffy nose, and sneezing)
  • vomiting
  • urinary tract infection
  • pain or swelling (inflammation) in your throat or mouth (oropharyngeal pain and pharyngitis)
  • abnormal liver function tests
  • muscle aches

The most common side effects of PROMACTA in children 1 year and older when used to treat persistent or chronic ITP are:

  • upper respiratory tract infection (symptoms may include runny nose, stuffy nose, and sneezing)
  • pain or swelling (inflammation) in your nose or throat (nasopharyngitis)

The most common side effects when PROMACTA is used in combination with other medicines to treat chronic HCV are:

  • low red blood cell count (anemia)
  • fever
  • tiredness
  • headache
  • nausea
  • diarrhea
  • decreased appetite
  • flu-like symptoms including fever, headache, tiredness, cough, sore throat, and body aches
  • trouble sleeping
  • feeling weak
  • cough
  • itching
  • chills
  • muscle aches
  • hair loss
  • swelling in your ankles, feet, and legs

The most common side effects associated with PROMACTA when used in combination with standard immunosuppressive therapy to treat severe aplastic anemia (SAA) reported more frequently than in patients with SAA when other medicines to treat SAA have not worked well enough are: 

  • abnormal liver function tests
  • rash
  • skin discoloration including darkening of skin patches (hyperpigmentation)

The most common side effects when PROMACTA is used to treat SAA when other medicines to treat SAA have not worked well enough are: 

  • nausea
  • feeling tired
  • cough
  • diarrhea 
  • headache

Laboratory tests may show abnormal changes to the cells in your bone marrow.

Tell your health care provider about any bruising or bleeding that happens while you take or after you stop taking PROMACTA.

Tell your health care provider if you have any side effect that bothers you or does not go away.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Approved Uses for PROMACTA® (eltrombopag)

PROMACTA is a prescription medicine used to treat adults and children 1 year and older with low blood platelet counts due to persistent or chronic immune thrombocytopenia (ITP) 

PROMACTA is a prescription medicine used to treat adults and children 1 year and older with low blood platelet counts due to persistent or chronic immune thrombocytopenia (ITP) when other medicines to treat your ITP or surgery to remove the spleen have not worked well enough. PROMACTA is used to try to raise platelet counts in order to lower your risk for bleeding.

PROMACTA is a prescription medicine used to treat low blood platelet counts in people with chronic hepatitis C virus (HCV) infection before and during treatment with interferon. PROMACTA should only be used in people with chronic HCV whose low blood platelet counts keep them from starting or continuing interferon-based therapy. It is not known if PROMACTA is safe and effective when used with other antiviral medicines that are approved to treat chronic HCV.

PROMACTA is a prescription medicine used to treat people with severe aplastic anemia (SAA) in combination with standard immunosuppressive therapy as the first treatment for adults and children 2 years of age and older. PROMACTA is also used to treat your SAA when other medicines have not worked well enough.

PROMACTA is not used to make platelet counts normal.

PROMACTA is for treatment of certain people with low platelet counts caused by persistent or chronic ITP, chronic HCV, or SAA, not for a precancerous condition called myelodysplastic syndromes (MDS) or low platelet counts caused by other conditions or diseases.

It is not known if PROMACTA is safe and effective when used with other antiviral medicines that are approved to treat chronic HCV.

It is not known if PROMACTA is safe and effective in children with chronic HCV or previously treated SAA, in children younger than 1 year with ITP, or children younger than 2 years when used in combination with standard immunosuppressive therapy as the first treatment for SAA.